David Einstein
@davidjeinstein
Followers
840
Following
349
Media
149
Statuses
1K
Disease Group Leader, GU Medical Oncology @BIDMChealth @df_hcc, Asst Prof @harvardmed, dad, cyclist, Far Side superfan
Massachusetts, USA
Joined January 2015
Optimal management of BCR was always hard for me to understand as a fellow… a decade later, it’s only gotten more complicated! But thanks to an amazing team, we outlined some paths forward for the field, out today in @JCO_ASCO! Concurrent with new PCWG4 @PCF_Science #PCF25
#EMBARK didn’t write the book📕on #BCR📈#ProstateCancer-it is merely the first chapter What do #BCR trials look like in the #PSMA🩻era? 30+experts met @theNCI🏛️ to provide a roadmap🧭 @JCO_ASCO @ASCO @PCF_Science @APCCC_Lugano @urotoday
https://t.co/ePbf8j7KQU
3
8
21
Akt inhibition may not be all about PTEN loss… @BIDMC_CancerCtr
A new therapeutic platform for patients with advanced #ProstateCancer ASCI member Steven P. Balk & team @harvardmed find AKT activation mitigates efficacy of AR targeted therapy in TMPRSS2:ERG fusion prostate cancer, suggesting combination therapy targeting AR and AKT in
0
0
7
When we get +OS, what % of the control arm will we need to see getting PARPi to make this meaningful?
🌟 new FDA approval for PARPi in metastatic castrate-sensitive #prostatecancer w/ BRCA2 today! 🚹nira + abi in pts vs abi in #BRCA2 mCSPC 🌀met rPFS; but only 36% in control got PARPi at progression ❓OS immature, sequencing w/ pluvicto/chemo, long-term AEs: MDS/AML
2
0
6
Time for a better crystal ball? (Or at least updated multivariable nomograms)
What’s high risk #BCR #ProstateCancer? PSA DT:best predictive biomarker in BCR; required for BCR trials PSMA 🤷🏻♂️undefined role EMA says HR is <12 months EMBARK says <9 mos Per @NCI BCR WG the data is most c/w <6 mos (see sankey👇 of MFS with NO therapy) https://t.co/KvNGyeRhZt
0
0
4
Welcome!
Congratulations and welcome to our incoming class of hematology/oncology fellows! We are excited to work with you!
0
0
31
Free Saturday night? https://t.co/Rzj1mPw7VE… I’m pulling out my trombone and my tux from college and joining the Longwood Symphony for Swan Lake. Amazing there are so many musicians in medicine, including @LisaHenske and @ml_barnett!
0
0
12
Proud to support the inimitable Dr. @neerajaiims for the @ASCO Nominating Committee! He is a globally respected & visionary clinical investigator and an exceptional leader. His kindness, humility, infectious optimism, and steadfast dedication to mentoring and sponsoring the next
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!
1
20
42
Lots of ❓s in defining benefits of “#oligomet” or “#MDT” therapy in #ProstateCancer ❓ADT+/-ARPI? How long? ❓PFS vs Eugonadal PFS? ❓how many mets? Where? 🔑❓what imaging 🩻❓ #PSMA mets🚫🟰CT/Bone scan mets https://t.co/LFMdSkoVln Std of Care? Or just something we can do?
2
15
29
Out now in @ClinCancerRes: targeting the AHR pathway to overcome intratumoral immune resistance in bladder cancer https://t.co/FOj77rj6NX 🚨We shouldn't give up on I/O in the treatment refractory setting in metastatic UC. As EV/P and DV ± T move earlier in metastatic UC,
2
6
25
ASPIRE trial--the trial we all need in this setting (ADT + ARPI +/- docetaxel): https://t.co/sVpvLCVGJX
0
1
6
Hot off the presses meta-analysis of docetaxel in mHSPC presented @uromigos #UromigosLive
https://t.co/KdvrHaSWtg
europeanurology.com
In metastatic hormone-sensitive prostate cancer, timing of metastases and volume of disease can offer guidance on treatment selection. Triplet therapy (androgen receptor pathway inhibitor [ARPI] + ...
1
13
39
STAMPEDE2 will have adaptive Lu177-PSMA dosing. Most radiation dose delivered after two cycles.
0
0
0
Michal Morris: "this is like looking at a baby just after birth and deciding you don't like it"
1
0
2
PSMAddition @ChrisSweens1 says, underwhelming and not surprising. "A study to get as much drug into pts as possible." #UromigosLive @Uromigos
2
9
14
Mock ODAC on the CREST and POTOMAC trials from #UromigosLive 2025. See the slides below to follow along with the discussion. Did our panel vote for or against approval? https://t.co/mzMt6lcIv7
0
26
41
Mock ODAC for 2025 HR NMIBC data at #UromigosLive (1) #CREST -BCG I/M +/- 2 yrs Sasanlimab (PD1) met EFS ❗️50/50 split for faculty who think approval should move forward (2) #POTOMAC -BCG I/M +/- 1 yr Durvalumab (PDL1) met DFS ❗️majority of faculty vote yes for approval 🏅
0
8
16
0
12
17
How to ever do sequencing studies with so many options coming down the pike? @Uromigos
0
7
15
Folks - we need your support! Give the video below a ❤️ to help my team (@Uromigos #TeamNorthAmerica) get a leg up in this year's competition ... great talks here from @TDorffOnc @cityofhope, @DrRosenbergMSK @MSKCancerCenter, McDermott @BIDMChealth & @kalasri3 @pmcancercentre!
Team America 🇺🇸 🇨🇦 have their educational video - with novel soundtrack - for Uromigos cup 🏆. Eurasia is winning. ♥️ =points. Surely it’s time for a win for the Americas. #UromigosLive @OncoAlert @montypal
0
17
50